- Cough, Mucus, and Respiratory Health: A Complete Guide - August 18, 2025
- Flogoprofen: what it's used for and how to take it - June 21, 2025
- What is Movicol oral solution in sachet used for and how to take it? - June 18, 2025
Tiziana Life Sciences announced a significant progress in the treatment of Alzheimer moderate.The first patient received intranasal foralumab in a clinical study.
Intranasal foralumab treatment offers a unique route to reducing brain inflammation and unlike other methods, this drug targets neuroinflammation of glial cells.
How intranasal foralumab works
Foralumab stimulates regulatory T cells, which cross the blood-brain barrier and there they help reduce microglia inflammation in the brain.
Ibuprofen Dr. Howard Weiner, Principal Investigator, highlighted the importance of this trial. “Targeting neuroinflammation represents a promising approach to modify disease progression,” he commented.
A milestone for Tiziana Life Sciences
Ivor Elrifi, CEO of Tiziana, noted that this treatment marks a milestone for Tiziana and that the company plans to expand its studies to patients with mild Alzheimer's. “We hope that this treatment will have a positive impact on patients and their families,” added Elrifi.
Support and funding of the study
Brigham and Women's Hospital Receives $4 Million Grant from the National Institutes of Health (NIH) which will allow continued research into intranasal foralumab.
The grant supports preclinical and clinical studies. The goal is to turn this innovative therapy into an effective solution for Alzheimer's disease.
Other uses of foralumab
In addition to Alzheimer's, Foralumab is being investigated for other inflammatory and autoimmune diseases and shown benefits in secondary progressive multiple sclerosis (na-SPMS).
An expanded access study in patients with this condition saw improvement or stability within six months, prompting the FDA to enroll 20 more patients in the program.
Alzheimer's is a global challenge affecting millions of people, but there are currently few therapeutic options for this stage of the disease.
